港股詳情

本頁面由Tiger Fintech (Singapore) Pte. Ltd.提供服務

醫藥外包概念

1,787.578

-5.464-0.30%

漲家數：2

跌家數：4

平家數：2

市盈率：- -

高：1,840.451

開：1,793.941

低：1,762.516

收：1,793.042

資料載入中...

藥明生物盤中異動股價大漲3.21%報24.100港元

藥明康德盤中異動大幅拉昇3.05%

午評：港股恒指漲2.54% 恒生科指漲3.69% 昭衍新藥漲超10%

【港股醫藥股震盪走高昭衍新藥漲近10%】港股醫藥股震盪走高，昭衍新藥漲近10%，榮昌生物漲超7%，凱萊英、康龍化成、君實生物等漲幅居前。

泰格醫藥盤中異動快速上漲5.00%報36.750港元

昭衍新藥盤中異動快速上漲5.09%報14.440港元

快訊：恒指高開0.89% 科指漲1.14%藥明生物漲超2%

翰森製藥(03692.HK)HS-10561膠囊臨牀試驗獲批

阿斯达克财经

翰森製藥獲批HS-10561膠囊臨牀試驗

翰森製藥(03692)：HS-10561膠囊獲國家藥品監督管理局簽發的藥物臨牀試驗批准通知書

頭對頭單藥擊敗K藥後，依沃西牽手輝瑞ADC

中證滬深港生物科技主題指數報1180.50點，前十大權重包含藥明生物等

【盟科藥業：全資子公司盟科美國對Medpace提起訴訟】盟科藥業公告稱，公司全資子公司盟科美國於2025年2月24日收到美國俄亥俄州南區聯邦地區法院西部分院起訴立案確認通知，盟科美國訴Medpace合同糾紛一案已完成起訴立案。盟科美國請求判令Medpace賠償因違反合同義務和不當行為導致的損失、成本和費用以及利息，具體金額將在庭審中證明。目前案件尚未開庭審理，最終實際影響需以後續法院判決或執行結果為準。公司已完成注射用MRX-4的中國III期臨牀試驗，本次訴訟事宜不涉及對該試驗的影響。

通化東寶(600867.SH)：注射用THDBH120獲降糖適應症Ib期臨牀試驗總結報告

通化東寶(600867.SH)：GLP-1/GIP雙靶點受體激動劑獲得降糖適應症Ib期臨牀試驗總結報告

賽諾菲(SNY.US)與梯瓦(TEVA.US)共同開發的duvakitug預計在下半年啓動3期臨牀試驗

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/BK1576/news?page=11"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK1576"},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1576\",,,,,undefined,":{"symbol":"BK1576","market":"HK","secType":"PLATE","nameCN":"醫藥外包概念","latestPrice":1787.5779,"timestamp":1741594084354,"preClose":1793.0419,"halted":0,"volume":80771814,"delay":0,"changeRate":-0.003047,"change":-5.463989,"pbRate":2.65369,"amount":1784097230,"amplitude":0.043465,"prevYearClose":1395.7731,"fiveDayClose":1689.63,"twentyDayClose":1618.242,"turnoverRate":0.006914,"marketCap":379404801152,"floatMarketCap":166674436992,"peRate":33.079805},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1576\",,,,,undefined,":{"symbol":"BK1576","high":1840.4508,"amplitude":0.043465,"preClose":1793.0419,"low":1762.5157,"pbRate":"2.65369","latestPrice":1787.5779,"volume":80771814,"delay":0,"open":1793.9412,"prevYearClose":1395.7731,"prevWeekClose":1793.042,"prevMonthClose":1699.456,"prevQuarterClose":1395.773,"fiveDayClose":1689.63,"twentyDayClose":1618.242,"sixtyDayClose":1409.843,"secType":"PLATE","market":"HK","turnoverRate":0.006914,"peRate":33.079805,"marketCap":379404801152,"floatMarketCap":166674436992,"timestamp":1741594084354,"nameCN":"醫藥外包概念"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK1576\",,,,undefined,":{"bkCode":"BK1576","up":2,"down":4,"flat":2},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK1576\",pageSize:16,pageCount:11,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2514907746","title":"藥明生物盤中異動 股價大漲3.21%報24.100港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2514907746","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514907746?lang=zh_tw&edition=fundamental","pubTime":"2025-02-26 13:07","pubTimestamp":1740546461,"startTime":"0","endTime":"0","summary":"2025年02月26日下午盘13时07分，药明生物股票出现异动，股价大幅上涨3.21%。截至发稿，该股报24.100港元/股，成交量2760.7万股，换手率0.67%，振幅3.21%。资金方面，该股资金流入2.96443亿港元，流出2.92098亿港元。药明生物股票所在的生物技术行业中，整体涨幅为1.48%。其相关个股中，创胜集团-B、科济药业-B、加科思-B涨幅较大，振幅较大的相关个股有创胜集团-B、科济药业-B、华昊中天医药-B，振幅分别为36.76%、28.32%、23.48%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502261307419630b5c4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502261307419630b5c4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1794554557.SGD","LU0043850808.USD","LU0348825331.USD","LU1880383366.USD","LU1242518857.USD","LU0051755006.USD","BK1589","LU0516423091.SGD","LU0140636845.USD","LU0572944931.SGD","LU0417516902.SGD","LU0708995583.HKD","LU0516422952.EUR","LU0359201612.USD","LU1242518931.SGD","LU1720050803.USD","LU0039217434.USD","LU0417516738.SGD","LU0823426308.USD","BK1141","SG9999002463.SGD","LU0856984785.SGD","LU0327786744.USD","LU0348735423.USD","LU0326950275.SGD","LU0823426480.USD","LU0516423174.USD","LU0588546209.SGD","IE00B0JY6N72.USD","LU0979878070.USD","LU0320764599.SGD","LU0052750758.USD","LU0819121731.USD","LU1688375341.USD","02269","LU2039709279.SGD","LU0359202008.SGD","SG9999002562.SGD","LU0307460666.USD","BK1610","LU0516422366.SGD","LU0456827905.SGD","LU0516422440.USD","BK1576","LU0456846285.SGD","BK1521","LU0181495838.USD"],"gpt_icon":1},{"id":"2514077467","title":"藥明康德盤中異動 大幅拉昇3.05%","url":"https://stock-news.laohu8.com/highlight/detail?id=2514077467","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514077467?lang=zh_tw&edition=fundamental","pubTime":"2025-02-26 13:06","pubTimestamp":1740546383,"startTime":"0","endTime":"0","summary":"2025年02月26日下午盘13时06分，药明康德股票出现异动，股价快速拉升3.05%。截至发稿，该股报62.600港元/股，成交量433.109万股，换手率1.12%，振幅2.47%。资金方面，该股资金流入1.38155亿港元，流出1.04408亿港元。药明康德股票所在的生物技术行业中，整体涨幅为1.48%。其相关个股中，创胜集团-B、科济药业-B、北海康成-B涨幅较大，振幅较大的相关个股有创胜集团-B、科济药业-B、华昊中天医药-B，振幅分别为36.76%、28.32%、23.48%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250226130623a25458fa&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250226130623a25458fa&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02359","LU2242644610.SGD","BK1583","LU0320764599.SGD","LU0052750758.USD","BK1576","LU2045819591.USD","BK1141","LU2125910500.SGD","LU1046422090.SGD","LU0708995583.HKD"],"gpt_icon":0},{"id":"2514071422","title":"午評：港股恒指漲2.54% 恒生科指漲3.69% 昭衍新藥漲超10%","url":"https://stock-news.laohu8.com/highlight/detail?id=2514071422","media":"新浪港股","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514071422?lang=zh_tw&edition=fundamental","pubTime":"2025-02-26 12:00","pubTimestamp":1740542400,"startTime":"0","endTime":"0","summary":"　　2月26日消息，港股三大指数高开高走。截至午间收盘，恒生指数涨2.54%，报23619.24点，恒生科技指数涨3.69%，国企指数涨2.63%。盘面上，科网股全线上涨，京东大涨逾7%，美团涨逾6%，阿里巴巴、哔哩哔哩涨超4%，小米、腾讯涨超3%；内房股普遍上涨，世茂集团超13%领涨；CXO概念股震荡走高，昭衍新药涨超10%。叠加前期A/H医疗服务板块估值处于历史低位+有主营业务托底，看好后续该板块持续受益AI合作催化。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2025-02-26/doc-inemurff3721133.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["MCHmain","YANG","HHImain","02833","HSImain","HSTECH","07226","MHImain","BK1141","603127","513600","BK0216","06127","HSCEI","BK1576","HSI"],"gpt_icon":0},{"id":"2514078441","title":"【港股醫藥股震盪走高 昭衍新藥漲近10%】港股醫藥股震盪走高，昭衍新藥漲近10%，榮昌生物漲超7%，凱萊英、康龍化成、君實生物等漲幅居前。","url":"https://stock-news.laohu8.com/highlight/detail?id=2514078441","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514078441?lang=zh_tw&edition=fundamental","pubTime":"2025-02-26 10:28","pubTimestamp":1740536907,"startTime":"0","endTime":"0","summary":"港股医药股震荡走高，昭衍新药涨近10%，荣昌生物涨超7%，凯莱英、康龙化成、君实生物等涨幅居前。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/02/26102848391749.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK1191","01877","BK1583","603127","LU1064131003.USD","002821","LU1969619763.USD","159718","06127","BK0216","BK1161","LU1064130708.USD","03759","BK1141","688180","BK0239","BK1515","06821","LU2148510915.USD","BK1574","09995","688331","LU2328871848.SGD","300759","BK0132","BK1576","LU1328615791.USD"],"gpt_icon":0},{"id":"2514958020","title":"泰格醫藥盤中異動 快速上漲5.00%報36.750港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2514958020","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514958020?lang=zh_tw&edition=fundamental","pubTime":"2025-02-26 09:50","pubTimestamp":1740534626,"startTime":"0","endTime":"0","summary":"2025年02月26日早盘09时50分，泰格医药股票出现异动，股价急速拉升5.00%。截至发稿，该股报36.750港元/股，成交量71.13万股，换手率0.58%，振幅4.29%。资金方面，该股资金流入1366.53万港元，流出677.275万港元。最近的财报数据显示，该股实现营业收入56.20亿港元，净利润9.02亿港元，每股收益1.04港元，毛利21.85亿港元，市盈率14.21倍。泰格医药股票所在的生物技术行业中，整体涨幅为0.29%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502260950279892d8eb&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502260950279892d8eb&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["03347","BK1141","BK1583","BK1576"],"gpt_icon":0},{"id":"2514817027","title":"昭衍新藥盤中異動 快速上漲5.09%報14.440港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2514817027","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514817027?lang=zh_tw&edition=fundamental","pubTime":"2025-02-26 09:36","pubTimestamp":1740533813,"startTime":"0","endTime":"0","summary":"2025年02月26日早盘09时36分，昭衍新药股票出现异动，股价大幅拉升5.09%。截至发稿，该股报14.440港元/股，成交量53.978万股，换手率0.45%，振幅5.24%。资金方面，该股资金流入558.46万港元，流出104.832万港元。昭衍新药股票所在的生物技术行业中，整体涨幅为0.16%。其相关个股中，创胜集团-B、科济药业-B、药明巨诺-B涨幅较大，振幅较大的相关个股有创胜集团-B、科济药业-B、华昊中天医药-B，振幅分别为14.71%、11.27%、5.30%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502260936539892d454&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502260936539892d454&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["06127","BK1141","BK1576"],"gpt_icon":0},{"id":"2514022564","title":"快訊：恒指高開0.89% 科指漲1.14%藥明生物漲超2%","url":"https://stock-news.laohu8.com/highlight/detail?id=2514022564","media":"新浪港股","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514022564?lang=zh_tw&edition=fundamental","pubTime":"2025-02-26 09:20","pubTimestamp":1740532800,"startTime":"0","endTime":"0","summary":"　　2月26日消息，美股周二个别发展，市场忧虑关税措施影响经济表现，科技股表现受压，标普500指数及纳指连续第四个交易日下跌，道指则表现向好，三大指数收市升跌不一。美元走势向下，美国十年期债息下滑至4.29厘水平，金价及油价亦出现调整。　　今日港股三大指数集体高开，恒生指数涨0.89%，报23238.34点，恒生科指涨1.14%，国企指数涨0.82%。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2025-02-26/doc-inemukxi3765772.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LU0516423091.SGD","LU1794554557.SGD","SG9999002463.SGD","LU0327786744.USD","LU0516422366.SGD","LU1242518931.SGD","LU0051755006.USD","HSImain","BK1576","HHImain","BK1521","02833","LU0043850808.USD","SG9999002562.SGD","LU0456827905.SGD","MHImain","LU0140636845.USD","LU0417516738.SGD","HSI","LU0588546209.SGD","LU0572944931.SGD","LU0326950275.SGD","IE00B0JY6N72.USD","LU0979878070.USD","LU0417516902.SGD","LU0320764599.SGD","LU0181495838.USD","LU0516423174.USD","LU0708995583.HKD","BK1610","BK1141","MCHmain","YANG","02269","LU0348735423.USD","LU1880383366.USD","BK1589","LU0348825331.USD","LU0359201612.USD","HSTECH","LU0823426480.USD","LU0823426308.USD","LU0307460666.USD","LU1720050803.USD","LU0516422440.USD","LU1688375341.USD","513600","LU0856984785.SGD","LU0516422952.EUR","LU0819121731.USD"],"gpt_icon":0},{"id":"2514013495","title":"翰森製藥(03692.HK)HS-10561膠囊臨牀試驗獲批","url":"https://stock-news.laohu8.com/highlight/detail?id=2514013495","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514013495?lang=zh_tw&edition=fundamental","pubTime":"2025-02-25 23:13","pubTimestamp":1740496380,"startTime":"0","endTime":"0","summary":"翰森制药(03692.HK) 公布，集团与广州麓鹏制药合作的1类小分子布鲁顿酪氨酸激酶抑制剂HS-10561胶囊获中国国家药品监督管理局签发的药物临床试验批准通知书，拟开展用于慢性自发性荨麻疹的临床试验。(de/d)(港股报价延迟最少十五分钟。沽空资料截至 2025-02-25 16:25。)AASTOCKS新闻","market":"sh","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20201021164015908_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20201021164015908_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1420091/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1589","BK1576","BK1141","BK1583","BK1191","03347","03692"],"gpt_icon":0},{"id":"2514062201","title":"翰森製藥獲批HS-10561膠囊臨牀試驗","url":"https://stock-news.laohu8.com/highlight/detail?id=2514062201","media":"财中社","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514062201?lang=zh_tw&edition=fundamental","pubTime":"2025-02-25 18:58","pubTimestamp":1740481132,"startTime":"0","endTime":"0","summary":"2月25日，翰森制药（03692）发布公告，宣布其与广州麓鹏制药有限公司合作的1类小分子布鲁顿酪氨酸激酶抑制剂HS-10561胶囊，已获得中国国家药品监督管理局签发的药物临床试验批准通知书。该临床试验计划用于慢性自发性荨麻疹的治疗，标志着公司在研发领域的重要进展。此次获批的HS-10561胶囊是公司在创新药物开发方面的又一里程碑，显示了公司在生物制药领域的实力与潜力。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202502253329160477.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1589","03347","03692","BK1576","BK1191","BK1141","BK1583"],"gpt_icon":0},{"id":"2514064671","title":"翰森製藥(03692)：HS-10561膠囊獲國家藥品監督管理局簽發的藥物臨牀試驗批准通知書","url":"https://stock-news.laohu8.com/highlight/detail?id=2514064671","media":"智通财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514064671?lang=zh_tw&edition=fundamental","pubTime":"2025-02-25 18:50","pubTimestamp":1740480644,"startTime":"0","endTime":"0","summary":"智通财经APP讯，翰森制药(03692)发布公告，于2025年2月24日，集团与广州麓鹏制药有限公司合作的1类小分子布鲁顿酪氨酸激酶抑制剂(BTKi) HS-10561胶囊获中国国家药品监督管理局(NMPA)签发的药物临床试验批准通知书，拟开展用于慢性自发性荨麻疹的临床试验。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1254168.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["03692","03347","BK1141","BK1191","BK1589","BK1576","BK1583"],"gpt_icon":0},{"id":"2514402095","title":"頭對頭單藥擊敗K藥後，依沃西牽手輝瑞ADC","url":"https://stock-news.laohu8.com/highlight/detail?id=2514402095","media":"医药地理","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514402095?lang=zh_tw&edition=fundamental","pubTime":"2025-02-25 17:36","pubTimestamp":1740476179,"startTime":"0","endTime":"0","summary":"依沃西+ADC联合治疗实体瘤2025年2月24日，Summit Therapeutics公布2024年财报，披露了研发管线最新进展，同时宣布与辉瑞达成临床合作，开展PD-1/VEGF依沃西+ADC联合治疗实体瘤的临床探索。伊沃西—创新药的“国货之光”伊沃西是全球首个“肿瘤免疫PD-1+抗血管VEGF”机制的双抗新药。击败K药后，依沃西临床试验最新进展Summit表示，仅在2024年，伊沃西就成为了多个医疗会议的焦点，获得了5场口头报告的机会，并发表了14篇论文，覆盖7种肿瘤类型。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250225203409abdc61da&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250225203409abdc61da&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["03347","BK1161","IE00B5MMRT66.SGD","BK1574","BK1576","09926","IE00B543WZ88.USD","IE00BPRC5H50.USD","BK1141","LU0348783233.USD","LU2488822045.USD","LU1720050803.USD","LU1794554557.SGD","LU0348784397.USD","BK1583","LU0417516571.SGD"],"gpt_icon":0},{"id":"2514682770","title":"中證滬深港生物科技主題指數報1180.50點，前十大權重包含藥明生物等","url":"https://stock-news.laohu8.com/highlight/detail?id=2514682770","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514682770?lang=zh_tw&edition=fundamental","pubTime":"2025-02-25 17:08","pubTimestamp":1740474516,"startTime":"0","endTime":"0","summary":"数据统计显示，中证沪深港生物科技主题指数近一个月上涨13.10%，近三个月上涨9.40%，年至今上涨12.38%。据了解，中证沪深港生物科技主题指数从内地与香港市场选取50家业务涉及生物药品、制药与生物科技服务等领域的上市公司作为指数样本公司，反映内地与香港市场生物科技主题上市公司证券的整体表现。从中证沪深港生物科技主题指数持仓样本的行业来看，生物药品占比40.60%、化学药占比23.94%、制药与生物科技服务占比23.91%、医疗器械占比11.56%。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/02/25170848371986.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["LU0417516902.SGD","LU1720050803.USD","LU0417516738.SGD","LU0456846285.SGD","LU0572944931.SGD","LU0327786744.USD","LU0051755006.USD","02269","LU0052750758.USD","LU0823426480.USD","IE00B0JY6N72.USD","LU0140636845.USD","LU0348735423.USD","LU0516423174.USD","LU1688375341.USD","SG9999002562.SGD","BK1610","159982","LU1242518931.SGD","SG9999002463.SGD","LU0823426308.USD","LU0708995583.HKD","LU1242518857.USD","BK1576","159837","LU0348825331.USD","LU0359202008.SGD","LU0307460666.USD","LU0516422440.USD","LU0856984785.SGD","LU0039217434.USD","LU1880383366.USD","LU0326950275.SGD","LU0516422366.SGD","LU0359201612.USD","LU0043850808.USD","LU0516422952.EUR","BK1141","LU1794554557.SGD","LU0819121731.USD","LU0181495838.USD","LU0516423091.SGD","LU0588546209.SGD","LU0320764599.SGD","LU2039709279.SGD","BK1589","399300","LU0456827905.SGD","LU0979878070.USD","BK1521"],"gpt_icon":1},{"id":"2514705049","title":"【盟科藥業：全資子公司盟科美國對Medpace提起訴訟】盟科藥業公告稱，公司全資子公司盟科美國於2025年2月24日收到美國俄亥俄州南區聯邦地區法院西部分院起訴立案確認通知，盟科美國訴Medpace合同糾紛一案已完成起訴立案。盟科美國請求判令Medpace賠償因違反合同義務和不當行為導致的損失、成本和費用以及利息，具體金額將在庭審中證明。目前案件尚未開庭審理，最終實際影響需以後續法院判決或執行結果為準。公司已完成注射用MRX-4的中國III期臨牀試驗，本次訴訟事宜不涉及對該試驗的影響。","url":"https://stock-news.laohu8.com/highlight/detail?id=2514705049","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514705049?lang=zh_tw&edition=fundamental","pubTime":"2025-02-25 16:51","pubTimestamp":1740473510,"startTime":"0","endTime":"0","summary":"盟科药业公告称，公司全资子公司盟科美国于2025年2月24日收到美国俄亥俄州南区联邦地区法院西部分院起诉立案确认通知，盟科美国诉Medpace合同纠纷一案已完成起诉立案。盟科美国请求判令Medpace赔偿因违反合同义务和不当行为导致的损失、成本和费用以及利息，具体金额将在庭审中证明。目前案件尚未开庭审理，最终实际影响需以后续法院判决或执行结果为准。公司已完成注射用MRX-4的中国III期临床试验，本次诉讼事宜不涉及对该试验的影响。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/02/25165148371308.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["03347","BK4127","BK1576","688373","MRX","BK1141","III","BK4134","BK0239","BK1583"],"gpt_icon":0},{"id":"2514541900","title":"通化東寶(600867.SH)：注射用THDBH120獲降糖適應症Ib期臨牀試驗總結報告","url":"https://stock-news.laohu8.com/highlight/detail?id=2514541900","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514541900?lang=zh_tw&edition=fundamental","pubTime":"2025-02-25 16:12","pubTimestamp":1740471148,"startTime":"0","endTime":"0","summary":"智通财经APP讯，通化东宝(600867.SH)公告，公司全资子公司东宝紫星(杭州)生物医药有限公司(简称“东宝紫星”)完成了一项关键Ib期临床试验(“在中国成人2型糖尿病患者中评价注射用THDBH120多次给药的安全性、耐受性、药代动力学和药效动力学的随机、双盲、安慰剂对照的Ib期临床研究”)并获得临床试验总结报告，研究结果显示达到主要终点目标。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1253996.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0196","BK0188","600867","BK1576","BK1141","BK0239","BK1583","03347"],"gpt_icon":0},{"id":"2514549320","title":"通化東寶(600867.SH)：GLP-1/GIP雙靶點受體激動劑獲得降糖適應症Ib期臨牀試驗總結報告","url":"https://stock-news.laohu8.com/highlight/detail?id=2514549320","media":"格隆汇","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514549320?lang=zh_tw&edition=fundamental","pubTime":"2025-02-25 16:09","pubTimestamp":1740470979,"startTime":"0","endTime":"0","summary":"格隆汇2月25日丨通化东宝公布，全资子公司东宝紫星（杭州）生物医药有限公司完成了一项关键Ib期临床试验并获得临床试验总结报告，研究结果显示达到主要终点目标。公司在获得注射用THDBH120药物临床试验批准后，根据国内化学药品创新药相关指导原则，近日完成了一项“在中国成人2型糖尿病患者中评价注射用THDBH120多次给药的安全性、耐受性、药代动力学和药效动力学的随机、双盲、安慰剂对照的Ib期临床研究”，研究结果达到了主要终点目标。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/02/25160948369004.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK0239","03347","600867","BK0188","BK4144","BK1141","GLP","BK0196","BK1576","BK4590","BK1583"],"gpt_icon":0},{"id":"2514803042","title":"賽諾菲(SNY.US)與梯瓦(TEVA.US)共同開發的duvakitug預計在下半年啓動3期臨牀試驗","url":"https://stock-news.laohu8.com/highlight/detail?id=2514803042","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514803042?lang=zh_tw&edition=fundamental","pubTime":"2025-02-25 14:33","pubTimestamp":1740465193,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，赛诺菲与梯瓦日前公布了其共同开发的在研单抗duvakitug在2b期临床试验RELIEVE UCCD中获得的详细结果。新闻稿表示，这一结果展现了duvakitug成为“best-in-class”疗法的潜力。两家公司预计在今年下半年启动3期临床试验。2b期临床试验数据显示，接受duvakitug治疗的UC患者中，36%的低剂量组和48%高剂量组患者实现临床缓解，此数值在安慰剂组仅为20%。靶向TL1A有望缓解IBD患者的过度免疫反应。赛诺菲与梯瓦在2023年达成合作，共同开发并商业化duvakitug，用于治疗UC和CD。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1253916.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["03347","BK4596","BK1576","BK4584","BK4559","BK1141","BK1583","BK4557","BK4585","BK4588","IE00BFXG1179.USD","BK4007","BK4566","TEVA","SNY"],"gpt_icon":0}],"pageSize":16,"totalPage":13,"pageCount":11,"totalSize":200}]}}